Peripheral stimulation of CCK-B receptors by BC264 induces a hyperexploration, dependent on the δ opioid system in the nucleus accumbens of rat

Neuropharmacology

Volumn 38, Issue 7, 1999, Pages 999-1007

  Daugé, Valérie ^a   Samir, Attoub ^b   Cupo, Annie ^c   Roques, B P ^a  

^a CNRS   (France)

^b BICHAT HOSPITAL   (France)

^c INSTITUT DE PHARMACOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

Author keywords

Opioid antagonists; Opioid antagonists; CCK, cholecystokinin; CCK LI: cholecystokinin like immunoreactivity; CCKB receptor agonists; Locomotor activity; Met LI CCK LI release; Met LI, Met enkephalin like immunoreactivity; Microdialysis; N.Acc., nucleus accumbens; Nucleus accumbens

Indexed keywords

BC 264; CHOLECYSTOKININ B RECEPTOR; CHOLECYSTOKININ RECEPTOR STIMULATING AGENT; METENKEPHALIN; NALOXONE; NALTRINDOLE; OPIATE RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; EMOTION; EXPLORATORY BEHAVIOR; HISTOLOGY; INTRAPERITONEAL DRUG ADMINISTRATION; LOCOMOTION; MALE; MOTIVATION; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RAT; STOMACH ACID SECRETION; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMALS; CHOLECYSTOKININ; EXPLORATORY BEHAVIOR; GASTRIC ACID; MALE; MICRODIALYSIS; NALTREXONE; NARCOTIC ANTAGONISTS; NUCLEUS ACCUMBENS; PEPTIDE FRAGMENTS; PERIPHERAL NERVOUS SYSTEM; RATS; RATS, WISTAR; RECEPTOR, CHOLECYSTOKININ B; RECEPTORS, CHOLECYSTOKININ; RECEPTORS, OPIOID, DELTA;

EID: 0033047204     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0028-3908(99)00028-3     Document Type: Article

References (45)

1. Anisman H., Kokkinidis L. Effects of scopolamine, D-amphetamine and other drugs affecting catecholamines on spontaneous alternation and locomotor activity in mice. Psychopharmacologia. 45:1975;55-63.
2. Bado A., Durieux C., Moizo L., Roques B.P., Lewin M.J.M. Cholecystokinin - A receptor mediation of food intake in cats. Am. J. Physiol. XX:1991;R693-R697.
3. Baber N.S., Dourish C.T., Hill D.R. The role of CCK, caerulein and CCK antagonists in nociception. Pain. 39:1989;307-328.
4. Calenco-Choukroun G., Daugé V., Gacel G., Féger J., Roques B.P. Opioid ∂ agonists and endogenous enkephalins induce different emotional reactivity than μ agonists after injection in the rat ventral tegmental area. Psychopharmacology. 103:1991;493-503.
5. Chang R.S.L., Lotti V.J. Characterization of an extremely potent and selective nonpeptide cholecystokinin antagonist. Proc.Natl Acad. Sci. USA. 83:1986;4923-4926.
6. Charpentier B., Durieux C., Pélaprat D., Dor A., Reibaud M., Blanchard J.C., Roques B.P. Enzyme resistant CCK analogs with high affinities for central receptors. Peptides. 9:1988;835-841.
7. Cooper S.J. Interactions between endogenous opioids and dopamine: implications for reward and aversion. Willner P., Scheel-Krüger J. The Mesolimbic Dopamine System: From Motivation to Action. 1991;331-366 John Wiley, Chichester.
8. Corp E.S., McQuada J., Moran T.H., Smith G.P. Characterization of type A and type B CCK receptor binding sites in rat vagus nerve. Brain Res. 623:1993;161-166.
9. Crawley J., Corwin R.L. Biological actions of chlolecystokinin. Peptides. 15:1994;731-755.
10. Crawley J.N., Kiss J.Z. Paraventricular nucleus lesions abolish the inhibition of feeding induced by systemic cholecystokinin. Peptides. 6:1985;927-935.
11. Crawley J.N., Hays S.E., Paul S.M. Vagotomy abolishes the inhibitory effects of cholecystokinin on rat exploratory behaviors. Eur. J. Pharmacol. 73:1981;379-380.
12. Crawley J.N., Fiske S.M., Durieux C., Derrien M., Roques B.P. Centrally administered cholecystokinin suppresses feeding through a peripheral-type receptor mechanism. J. Pharmacol. Exp. Ther. 257:1991;1076-1080.
13. -16 mole level. J. Neuroimmunol. 8:1985;57-67.
14. Daugé V., Rossignol P., Roques B.P. Comparison of the behavioural effects induced by administration in rat nucleus accumbens or nucleus caudatus of selective μ and ∂ opioid peptides or kelatorphan an inhibitor of enkephalin-degrading-enzymes. Psychopharmacology. 96:1988;343-352.
15. Daugé V., Böhme G.A., Crawley J.N., Durieux C., Stutzmann J.M., Feger J., Blanchard J.C., Roques B.P. Investigation of behavioral and electrophysiological responses induced by selective stimulation of CCKB receptors using a new highly potent CCK analog, BC264. Synapse. 6:1990;73-80.
16. Daugé V., Roques B.P. Opioid and CCK systems in anxiety and reward. Bradwejn J., Vasar E. Cholecystokinin and Anxiety. From Neuron to Behaviour. 1995;151-171 Neuroscience Intelligence Unit, Biomedical Publishers, R.G. Landes Company, Austin.
17. Daugé V., Corringer P.J., Roques B.P. CCKA, but not CCKB, agonists suppress the hyperlocomotion induced by endogenous enkephalins, protected from enzymatic degradation by systemic RB101. Pharmacol. Biochem. Behav. 50:1995;133-139.
18. Daugé V., Mauborgne A., Cesselin F., Fournié-Zaluski M.C., Roques B.P. The dual peptidase inhibitor RB101 induces a long-lasting increase in the extracellular level of Met-enkephalin-like material in the nucleus accumbens of freely moving rats. J. Neurochem. 67:1996;1301-1308.
19. Derrien M., McCort-Tranchepain I., Ducos B., Roques B.P., Durieux C. Heterogeneity of CCK-B receptors involved in animals models of anxiety. Pharmacol. Biochem. Behav. 49:1994;133-141.
20. Dubrasquet J.M., Bataille D., Gespach C. Oxyntomodulin (glucagon-37 or bioactive enteroglucagon): a potent inhibitor of pentagastrin stimulated acid secretion in rat. Biosci. Res. 2:1982;391-395.
21. Fournié-Zaluski M.C., Coric P., Turcaud S., Lucas E., Noble F., Maldonado R., Roques B.P. Mixed-inhibition-prodrug as a new approach towards systemically active inhibitors of enkephalin degrading enzymes. J. Med. Chem. 35:1992;2473-2481.
22. Gacel G.A., Fellion E., Baamonde A., Daugé V., Roques B.P. Synthesis, biochemical and pharmacological properties of BUBUC, a highly selective and systemically active agonist for in vivo studies of ∂ opioid receptors. Peptides. 11:1990;983-988.
23. Hill D.R., Shaw T.M., Woodruff G.N. Species differences in the localization of 'peripheral' type cholecystokinin receptors in the brain. Neurosci. Lett. 79:1987;286-289.
24. Itoh S., Katsuura G. Behavioral effect of cholecystokinin octapeptide in vagotomized rats. Can. J. Physiol. Pharmacol. 64:1986;745-747.
25. Itoh S., Lal H. Influences of cholecystokinin and analogues on memory processes. Drug Dev. Res. 21:1990;257-276.
26. Kalivas P.W., Widerlöv E., Stanley D., Breese G., Prange Jr A.J. Enkephalin action on the mesolimbic system: a dopamine-dependent and dopamine-independent increase in locomotor activity. J. Pharmacol. Exp. Ther. 227:1983;229-237.
27. Katz R.J., Schmaltz K. Dopaminergic involvement in attention: a novel animal model. Prog. Neuropsychopharmacol. 4:1981;585-590.
28. Kopin A.S., Lee Y.M., McBride E.W. et al. Expression, cloning and characterization of the canine parietal cell gastrin receptor. Proc. Natl. Acad. Sci. USA. 89:1992;3605-3609.
29. Ladurelle N., Keller G., Blommaert A., Roques B.P., Daugé V. The CCKB agonist, BC264, increases dopamine in the nucleus accumbens and facilitates motivation and attention after intraperitoneal injection in rats. Eur. J. Neurosci. 9:1997;1804-1814.
30. Lee Y.M., Beinborn M., McBride E.W., Lu M., Kolakowski L.F., Kopin A.S. The human brain cholecystokinin-B/gastrin receptors. J. Biol. Chem. 268:1993;8164-8169.
31. Léna I., Roques B.P., Durieux C. Dual modulation of dopamine release from anterior nucleus accumbens through cholecystokinin-B receptors subsites. J. Neurochem. 68:1997;162-168.
32. Léna, I., Simon, H., Roques, B.P., Daugé, V. Opposing effects of two CCKB agonists on the retrieval phase of a two-trial memory task after systemic injection in the rat. Neuropharmacology (in press).
33. Menozzi D., Gardner J.D., Jensen R.T., Maton P.N. Properties of receptors for gastrin and CCK on gastric smooth muscle cells. Am. J. Physiol. 257:1989;G73-G79.
34. Million M.E., Léna I., Da Nascimento S. et al. Development of new potent agonists able to interact with two postulated subsites of the cholecystokinin CCKB receptor. Lett. Pept. Sci. 4:1997;407-410.
35. Moran T.H., Robinson P.H., Goldrich M.S., McHungh P.R. Two brain cholecystokinin receptors: implications for behavioral actions. Brain Res. 362:1986;175-179.
36. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates. 1986;Academic Press, New York.
37. 125I] Bolton Hunter CCK8. Functional significance of subregional distribution. Neurochem. Int. 10:1987;495-508.
38. Portoghese P.S., Sultana M., Takemori A.E. Naltrindole, a highly selective and potent non peptide ∂ opioid receptor antagonist. Eur. J. Pharmacol. 146:1988;185-186.
39. Pu S-F., Zhuang H-X., Han J-S. Cholecystokinin octapeptide (CCK8) antagonizes morphine analgesia in nucleus accumbens of the rat via the CCK-B receptor. Brain Res. 657:1994;159-164.
40. Robinson T.E., Whishaw I.Q. Normalization of extracellular dopamine in the striatum following recovery from a partial unilateral 6-OHDA lesion of the substantia nigra: a microdialysis study in freely moving rats. Brain Res. 450:1988;209-224.
41. Smadja C., Ruiz F., Coric P., Fournié-Zaluski M.C., Roques B.P., Maldonado R. CCK-B receptors in the limbic system modulate the antidepressant-like effects induced by endogenous enkephalins. Psychopharmacology. 132:1997;227-236.
42. Song M., Wong H., Ohning G., Walsh J.H. Immunohistochemical localization of the gastrin/CCK-B receptor in the rat stomach. Gastroenterology. 110:1996;A1120.
43. Wang Z-j., Roa Z-r., Shi J-w Tyrosine hydroxylase-, neurotensin-, or cholecystokinin-containing neurons in the nucleus tractus solitarii send projection fibers to the nucleus accumbens in the rat. Brain Res. 578:1992;347-350.
44. Wank S.A., Pisegna J.R., deWeerth A. Cholecystokinin receptor family. Molecular cloning, structure and functional expression in rat, guinea-pig and human. Ann. NY Acad. Sci. 713:1994;49-66.
45. Wise R.A., Bozarth M.A. A psychomotor stimulant theory of addiction. Psychol. Rev. 30:1987;469-492.